Summary by Moomoo AI
Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $7,250,000 to $10,000,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $7,222,741 worth of common stock within the last 12 months and is now eligible to sell an additional $2,855,314. The prospectus supplement, which amends the prior prospectus dated November 29, 2023, and supplemented on March 19, 2024, specifies that the company will not sell more than one-third of the aggregate market value of its common stock held by non-affiliates in any 12-month period, which is capped at $10,078,055, as long as the public float remains below $75 million. The filing also notes the high degree of risk involved in investing in their common stock and includes a reference to the risk factors detailed in the prior prospectus supplement.
